I'll start, and then I'll let you comment, Madeline.
Very quickly, I've spent a lot of time working with Health Canada, many years, and also the provincial governments. I have been profoundly shocked, perhaps, on the lack of progress in many issues. We seem to have the same meetings with the same discussions time and time and time again.
There was a meeting in March, a stakeholder consultation, a Health Canada round on progressive licensing. I missed that. I told them I would come to talk to them about what I've done. I met David Lee, the lead senior counsel there, and Maurica Maher, who's head of the progressive licensing framework. I actually think those guys have the right attitude to this, but what they need to do is focus on solutions. It's great to have a framework, a legislative framework, but it has to be solution-directed.
If you want safer drugs for women, pick a drug, pick a group of women to test the safety and the new surveillance system on. It's the same with children, the same with men—let's not forget men. These safety issues are for all patients and are important. There are gender and age issues that are important, but it's important that we look to decide which safety solutions we would like to come up with first. So have solutions in place that you're aiming for, not just a framework for licensing. It's great, but it looks a little bit like a Cadillac from, frankly, a car dealer who hasn't ever really built anything like that before.
They need to recognize that we need to have very specific objectives to improve the safety. Maybe it's about a vaccine like the HPV vaccine, to understand the determinants of the deaths that have occurred or other risks that exist. There are many, many drugs and many reactions to choose from. We just need to pick two or three and get our feet wet.